GlassScriptPhysician profile
Anusha Vuppala
NPI 1659724367
$8,397.99
in general payments reported to CMS, 2019-2025
22 companies · $1,262 in 2025
The $1,262 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $78.82 · 2021: $373 · 2022: $1,122 · 2023: $2,922 · 2024: $2,641 · 2025: $1,262.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,542 · Education: $283.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,541.51 |
| Education | $283.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,062.93 | 2021-2025 | Enbrel, Tavneos, Evenity |
| Janssen Biotech, INC. | $1,081.40 | 2022-2025 | Tremfya, Simponi Aria, Stelara |
| Abbvie INC. | $1,048.12 | 2022-2025 | Rinvoq, Skyrizi |
| Novartis Pharmaceuticals Corporation | $598.28 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $598.22 | 2022-2025 | Acthar |
| Ucb, INC. | $515.46 | 2022-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $385.52 | 2022-2025 | |
| Radius Health, INC. | $361.95 | 2023-2025 | Tymlos |
| Lilly USA, LLC | $276.27 | 2023-2025 | Taltz |
| Astrazeneca Pharmaceuticals LP | $268.80 | 2022-2025 | Saphnelo |
| Glaxosmithkline, LLC. | $233.08 | 2020-2025 | Benlysta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $184.58 | 2021-2024 | Cyltezo, Spevigo |
| Aurinia Pharma U.S., INC. | $156.82 | 2021-2025 | Lupkynis |
| E.R. Squibb & Sons, L.L.C. | $121.17 | 2023-2025 | Orencia |
| Alexion Pharmaceuticals, INC. | $105.20 | 2023-2025 | Strensiq |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $87.75 | 2020-2023 | Actemra |
| Fresenius Kabi USA, LLC | $82.57 | 2023-2025 | Idacio |
| Organon LLC | $76.61 | 2023-2024 | Hadlima, Renflexis |
| Sandoz INC. | $66.90 | 2023-2024 | Hyrimoz |
| Ani Pharmaceuticals, INC. | $43.70 | 2024-2025 | Purified Cortrophin Gel |
| Eisai INC. | $21.84 | 2023 | |
| Kiniksa Pharmaceuticals International, Plc | $20.82 | 2024 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anusha Vuppala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.